JP2013534425A5 - - Google Patents

Download PDF

Info

Publication number
JP2013534425A5
JP2013534425A5 JP2013518762A JP2013518762A JP2013534425A5 JP 2013534425 A5 JP2013534425 A5 JP 2013534425A5 JP 2013518762 A JP2013518762 A JP 2013518762A JP 2013518762 A JP2013518762 A JP 2013518762A JP 2013534425 A5 JP2013534425 A5 JP 2013534425A5
Authority
JP
Japan
Prior art keywords
nucleotides
strand
less
dsrna
isolated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013518762A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013534425A (ja
JP5976643B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/042820 external-priority patent/WO2012006243A2/en
Publication of JP2013534425A publication Critical patent/JP2013534425A/ja
Publication of JP2013534425A5 publication Critical patent/JP2013534425A5/ja
Application granted granted Critical
Publication of JP5976643B2 publication Critical patent/JP5976643B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013518762A 2010-07-06 2011-07-01 二本鎖rnaによるベータ−カテニンの特異的阻害に対する方法と組成物 Expired - Fee Related JP5976643B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36177610P 2010-07-06 2010-07-06
US61/361,776 2010-07-06
PCT/US2011/042820 WO2012006243A2 (en) 2010-07-06 2011-07-01 Methods and compositions for the specific inhibition of beta-catenin by double-stranded rna

Publications (3)

Publication Number Publication Date
JP2013534425A JP2013534425A (ja) 2013-09-05
JP2013534425A5 true JP2013534425A5 (OSRAM) 2014-08-14
JP5976643B2 JP5976643B2 (ja) 2016-08-24

Family

ID=45441761

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013518762A Expired - Fee Related JP5976643B2 (ja) 2010-07-06 2011-07-01 二本鎖rnaによるベータ−カテニンの特異的阻害に対する方法と組成物

Country Status (9)

Country Link
US (5) US8815825B2 (OSRAM)
EP (4) EP3587579B1 (OSRAM)
JP (1) JP5976643B2 (OSRAM)
AU (1) AU2011276365B2 (OSRAM)
CA (2) CA2804214C (OSRAM)
DK (3) DK2591105T3 (OSRAM)
ES (3) ES2734743T3 (OSRAM)
PT (1) PT3587579T (OSRAM)
WO (1) WO2012006243A2 (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2860676A1 (en) 2012-01-09 2013-07-18 Novartis Ag Organic compositions to treat beta-catenin-related diseases
EP3265179A4 (en) * 2015-03-04 2018-07-18 The University of Chicago Beta-catenin inhibitors in cancer immunotherapy
US10821112B2 (en) 2016-03-16 2020-11-03 Dicerna Pharmaceuticals, Inc. Compositions and methods for the treatment of a beta-catenin-associated disease or disorder
MA45469A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Acides nucléiques de bêta-caténine et leurs utilisations
AU2017368050A1 (en) 2016-11-29 2019-06-20 Puretech Lyt, Inc. Exosomes for delivery of therapeutic agents
NZ757538A (en) * 2017-03-28 2023-07-28 Dicerna Pharmaceuticals Inc Reducing beta-catenin expression to potentiate immunotherapy
US10407681B2 (en) * 2017-03-28 2019-09-10 The United States Of America, As Represented By The Secretary Of Agriculture Plant-mediated silencing of a fatty acid and retinoid binding protein in Pratylenchus penetrans
CN111225922B (zh) * 2017-10-18 2023-07-18 迪克纳制药公司 β连环蛋白核酸抑制剂分子
EP3714054A1 (en) * 2017-11-20 2020-09-30 Alnylam Pharmaceuticals, Inc. Serum amyloid p component (apcs) irna compositions and methods of use thereof
AU2019205904A1 (en) * 2018-01-05 2020-06-18 Dicerna Pharmaceuticals, Inc. Reducing beta-catenin and IDO expression to potentiate immunotherapy
EP3740248A4 (en) * 2018-03-02 2022-01-26 Dicerna Pharmaceuticals, Inc. Methods and compositions for treating bile duct paucity-associated conditions
US10961534B2 (en) 2018-07-13 2021-03-30 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating porphyria
AU2022316139A1 (en) * 2021-07-23 2024-01-18 Alnylam Pharmaceuticals, Inc. Beta-catenin (ctnnb1) irna compositions and methods of use thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
WO1992007065A1 (en) 1990-10-12 1992-04-30 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Modified ribozymes
US5652094A (en) 1992-01-31 1997-07-29 University Of Montreal Nucleozymes
US6326487B1 (en) 1995-06-05 2001-12-04 Aventis Pharma Deutschland Gmbh 3 modified oligonucleotide derivatives
US6218108B1 (en) 1997-05-16 2001-04-17 Research Corporation Technologies, Inc. Nucleoside analogs with polycyclic aromatic groups attached, methods of synthesis and uses therefor
US6248878B1 (en) 1996-12-24 2001-06-19 Ribozyme Pharmaceuticals, Inc. Nucleoside analogs
US7829693B2 (en) * 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
US8273866B2 (en) 2002-02-20 2012-09-25 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA)
US20030064384A1 (en) * 2001-04-02 2003-04-03 Mien-Chie Hung Beta-catenin is a strong and independent prognostic factor for cancer
US20060019917A1 (en) * 2001-05-18 2006-01-26 Sirna Therapeutics, Inc. RNA interference mediated inhibition of stromal cell-derived factor-1 (SDF-1) gene expression using short interfering nucleic acid (siNA)
JP4912873B2 (ja) * 2003-04-09 2012-04-11 アルナイラム ファーマシューティカルズ, インコーポレイテッド iRNA複合体
CA2521464C (en) 2003-04-09 2013-02-05 Alnylam Pharmaceuticals, Inc. Irna conjugates
US20070265220A1 (en) 2004-03-15 2007-11-15 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
WO2005089287A2 (en) 2004-03-15 2005-09-29 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded rna
EP1752536A4 (en) * 2004-05-11 2008-04-16 Alphagen Co Ltd POLYNUCLEOTIDE CAUSING RNA INTERFERENCE AND METHOD OF REGULATING GENE EXPRESSION WITH THE USE OF THE SAME
US20080213891A1 (en) 2004-07-21 2008-09-04 Alnylam Pharmaceuticals, Inc. RNAi Agents Comprising Universal Nucleobases
WO2006031977A2 (en) * 2004-09-13 2006-03-23 The Regents Of The University Of California Inhibition of pancreatic cancer cell growth
US20090176725A1 (en) * 2005-08-17 2009-07-09 Sirna Therapeutics Inc. Chemically modified short interfering nucleic acid molecules that mediate rna interference
US20090018097A1 (en) 2005-09-02 2009-01-15 Mdrna, Inc Modification of double-stranded ribonucleic acid molecules
WO2007031091A2 (en) * 2005-09-15 2007-03-22 Santaris Pharma A/S Rna antagonist compounds for the modulation of p21 ras expression
WO2008109369A2 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting tnf gene expression and uses thereof
JP2010524486A (ja) * 2007-05-01 2010-07-22 サンタリス ファーマ アー/エス β−カテニンを調節するためのRNAアンタゴニスト化合物
US20100239546A1 (en) * 2007-06-15 2010-09-23 Beth Israel Deaconess Medical Center Bacterial mediated tnf alpha gene silencing
TWI455944B (zh) * 2008-07-01 2014-10-11 Daiichi Sankyo Co Ltd 雙股多核苷酸
JP2012005734A (ja) 2010-06-28 2012-01-12 Panasonic Corp 電気掃除機用吸込具及びそれを備えた電気掃除機
JP6043285B2 (ja) 2010-08-02 2016-12-14 サーナ・セラピューティクス・インコーポレイテッドSirna Therapeutics,Inc. 低分子干渉核酸(siNA)を用いたカテニン(カドヘリン結合型タンパク質)β1(CTNNB1)遺伝子発現のRNA干渉媒介性阻害

Similar Documents

Publication Publication Date Title
JP2013534424A5 (OSRAM)
JP2013534425A5 (OSRAM)
JP7307137B2 (ja) GST-π遺伝子を調節するためのRNA干渉剤
JP7109416B2 (ja) 二本鎖rnaによるグリコール酸オキシダーゼ(hao1)の特異的阻害に関する方法および組成物
US8470796B2 (en) Treatment of cancer by inhibition of IGFBPs and clusterin
JP2022159552A (ja) iNOS阻害組成物および乳がん治療薬としてのその使用
JP2007529224A5 (OSRAM)
RU2013148024A (ru) Композиции и способы ингибирования экспрессии гена tmprss6
SG170780A1 (en) Compositions and methods for inhibiting expression of eg5 gene
JP2010537639A (ja) 非対称性干渉rnaの組成物およびその使用
SG171676A1 (en) Compositions and methods for inhibiting expression of the pcsk9 gene
JP2010532163A5 (OSRAM)
CN102719432B (zh) 特异性抑制肿瘤凋亡抑制基因Bcl2的双链不对称小核酸干扰分子asiRNA及其应用
WO2017068790A1 (ja) 核酸複合体
JP2022031642A (ja) アンチセンスオリゴヌクレオチド
US8193333B2 (en) Cancer therapy using Bcl-Xl-specific siNA
JP2007530431A5 (OSRAM)
EP2064328B1 (en) Sensitization of cancer cells to therapy using sina targeting genes from the 1p and 19q chromosomal regions
WO2017191021A1 (en) The incrna meg3 for therapy and diagnosis of cardiac remodelling
KR101993377B1 (ko) Bcl2 유전자 및 bi-1 유전자의 발현을 동시에 억제하는 핵산
WO2023001234A1 (en) Modified small interfering rna molecules with reduced off-target effects
CN107709561A (zh) 修饰的siRNA及含有该修饰的siRNA的药物组合物
EP3680334A1 (en) Double-stranded rna molecule targeting ckip-1 and use thereof
CN101173275B (zh) 抑制sars冠状病毒m蛋白基因表达的小干扰rna及其编码基因与应用
US20250179497A1 (en) Use of dinucleotide repeat rnas to treat cancer